Abstract Vitamin D insufficiency is highly prevalent in the U.S., particularly among colorectal cancer (CRC) patients. These low levels of vitamin D are concerning given increasing evidence that vitamin D may have health benefits beyond skeletal outcomes. Prospective observational studies suggest that higher vitamin D levels are associated with lower risk of incident CRC and improved survival for patients with established CRC, and randomized clinical trials are urgently needed to establish causality. Moreover, there remains a great need to improve prognosis for patients with CRC, and investigating vitamin D as a potential therapy is an attractive option in regards to safety and cost, particularly in this era of expensive and often toxic anti-neoplastic agents. In this review the evidence regarding the activity of vitamin D in CRC will be summarized, spanning preclinical, epidemiological, and clinical studies, and future research directions will be discussed.
Introduction
Epidemiological and scientific research indicates that diet and lifestyle factors have a significant effect on the development of colorectal cancer (CRC). Vitamin D, in particular, has been the subject of increasing academic and media interest as a result of abundant preclinical and observational data revealing its anti-neoplastic properties and the potential association of higher levels of vitamin D with reduced risk of CRC and improved survival. Several sources of vitamin D exist, including synthesis in the skin after exposure to ultraviolet (UV)-B radiation from sunlight, dietary sources, and vitamin D supplements. These inputs of vitamin D3 from the skin and intestinal tract are converted to 25- Binding of the nuclear vitamin D receptor (VDR) by calcitriol leads to dimerization with the retinoic-acid receptor (RXR), and to binding of the complex to vitamin D response elements (VDREs) located in promoters and regulatory regions of target genes. Although the most well-studied function of vitamin D is control of calcium and phosphate metabolism to maintain skeletal health, research over the last several years has revealed that 1α-hydroxylase and VDR are present in most cells of the body [1] , including CRC cells [2] [3] [4] , and that VDR also regulates target genes involved in inducing differentiation and apoptosis [5, 6] and inhibiting proliferation [7] , angiogenesis [8, 9] , and metastatic potential [10, 11] . These anti-neoplastic actions of vitamin D, the presence of VDR diffusely in normal and cancer cells, and the extrarenal distribution of 1α-hydroxylase all suggest that calcitriol can be synthesized locally within cancer cells to yield high concentrations within the tumor for intracrine and autocrine anti-cancer effects.
Given the above hypothesis, it is concerning that 77 % of Americans are currently vitamin D insufficient [12] . This rate may be rising as a result of increased use of sunscreen for skincancer prevention, reduced outdoor activity, and higher prevalence of obesity, among other factors. In an attempt to address these concerns, [13] (1 ng mL
), on the basis of the minimum amount required to maintain skeletal health. They concluded that there was insufficient evidence to support the objective of higher levels of vitamin D for chronic disease prevention and treatment. In contrast, the Endocrine Society recommended target 25(OH)D levels of ≥30 ng mL
, with levels <20 ng mL −1 regarded as deficient [14••] . These differences in the definition of vitamin D deficiency, and the ongoing controversy regarding optimum levels, emphasize the importance of further understanding the biological mechanisms of the function of vitamin D in CRC development and progression, and the critical need for rigorously designed, randomized clinical trials of chemoprevention and cancer treatment to establish vitamin D as a therapeutic option for CRC. In this review, we will summarize the scientific, epidemiological, and clinical progress to date in this field, and emphasize important future research directions that will improve our understanding of the relevant molecular pathways and potentially improve the prognosis of patients with CRC.
Vitamin D Activity in the Laboratory
Preclinical studies reveal that well-differentiated CRC cell lines have higher VDR expression [15] and that the antiproliferative effects of vitamin D seem to be greatest in cell lines that express high levels of VDR [16] , consistent with the hypothesis described above that local production of calcitriol may be directly involved in cancer pathogenesis. Vitamin D inhibits growth and promotes differentiation of CRC cell lines and xenografts [8, [17] [18] [19] [20] , and rats maintained on a diet enriched in calcitriol develop fewer intestinal tumors and metastases compared with control animals [11, 21] . Moreover, treatment of Apc Min mice with vitamin D or a synthetic analog reduces the size of intestinal adenomas [22] , which is increased in Apc
Although abundant evidence implicates vitamin D in CRC biology, the exact underlying mechanisms and pathways remain unclear. Beyond the direct effects on proliferation, cell differentiation, apoptosis, and metastatic potential mentioned above, several intriguing studies reveal that vitamin D can counteract aberrant WNT-β-catenin signaling, which is known to be part of the etiology of CRC, by inhibiting nuclear translocation of β-catenin, sequestering β-catenin at the membrane, and increasing levels of the extracellular WNT inhibitors DICCKOPF1 and DICKKOPF4 [25••] . Chronic inflammation is also a known risk factor for development and progression of CRC, and vitamin D exerts several antiinflammatory effects via down-regulation of nuclear factor (NF)-K B activity, increased production of anti-inflammatory interleukin (IL)-10, and reduced production of proinflammatory IL-6, IL-12, interferon-γ, and tumor necrosis factor (TNF)-α [26] . Moreover, vitamin D inhibits cyclooxygenase (COX) expression and reduces prostaglandin signaling, which not only suppresses inflammation but also reduces prostaglandin E 2 -induced hypoxia-inducible factor (HIF)-1α expression, leading to inhibition of angiogenesis [27] . Vitamin D also directly reduces expression of vascular endothelial growth factor (VEGF) [28] , and VDR-null mice have increased expression of pro-angiogenic factors including VEGF, HIF-1α, and platelet-derived growth factor (PDGF) [29] .
Further mechanistic and genetic studies are required to elucidate the extensive and intricate interactions that seem to characterize the function of vitamin D in CRC. The exact transcriptional targets of VDR, and even whether vitamin D acts directly on epithelial cells or within the tumor environment or both, remain unknown, and the effects of germline polymorphisms in vitamin-D-pathway genes on vitamin D metabolism and action are unclear. The effect of vitamin-Dbinding protein (VDBP, encoded by GC), to which 25(OH)D is bound in the circulation, is also uninvestigated, and it is uncertain whether total 25(OH)D levels or free or bioavailable 25(OH)D levels are the relevant substrate for vitamin D activity in cancer cells. Studies addressing these important questions are currently in progress.
Vitamin D in CRC Prevention
Overall, epidemiology findings have supported the scientific observations above. Multiple prospective studies reveal that individuals with higher plasma levels of total 25(OH)D have a significantly reduced risk of CRC compared with those with low plasma levels [30] [31] [32] [33] [34] [35] . In a meta-analysis of five epidemiology studies, individuals with serum 25(OH)D ≥33 ng mL −1 had a 50 % lower risk of CRC compared with those with levels ≤12 ng mL −1 (P<0.01) [36] . Two other randomized, placebo-controlled trials of vitamin D supplementation, designed primarily to investigate fracture risk, have reported results of secondary endpoints of cancer risk or mortality (Table 1 ). In the first trial, 2686 subjects were randomized to receive 100,000 IU of vitamin D3 versus placebo every four months [40] , and an age-adjusted RR of 0.62 (95 % CI, 0.24-1.60) for colon-cancer mortality was obtained with vitamin D compared with placebo (seven versus 11 colon cancer deaths, respectively). The second randomized trial evaluated the combination of vitamin D 1100 IU day −1 + calcium 1400-1500 mg day −1 versus calcium alone versus placebo for 1179 healthy post-menopausal women living in Nebraska, and obtained a 60 % reduction in all-cancer risk (including CRC) for the vitamin D group (P<0.03) [41] . Despite the fairly consistent evidence above, caution must be maintained, because most of the studies were observational in nature and CRC was a secondary end point in the randomized trials. Moreover, several large meta-analyses of plasma 25(OH)D concentrations and other cancer types have failed to find significant inverse associations [42, 43] , with some even reporting increased risk of prostate [44] and pancreatic cancer [45] with higher levels of 25(OH)D. Clearly, larger randomized placebo-controlled studies designed primarily to assess the effect of sufficiently high doses and duration of vitamin D on CRC risk, with adequate sample size and power, are urgently needed to determine whether vitamin D truly has chemopreventive activity. The Vitamin D and Omega-3 Trial (VITAL) is such an ongoing phase III clinical trial, which recently completed its planned accrual of 25,875 healthy subjects aged 50 years and older (ClinicalTrials.gov identifier NCT01169259). VITAL involves a 2×2 randomization to vitamin D3 2000 IU day −1 or fish oil 1 g day −1 compared Table 2 summarizes the six prospective epidemiology studies that have been performed on CRC patients to try and address this knowledge gap. The first study evaluated 304 CRC patients in the Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS) who had blood available for analysis, and found that those with circulating prediagnostic 25(OH)D levels in the highest quartile had a multivariable HR for overall mortality of 0.52 (95 % CI, 0.29-0.94; P trend=0.02) [46] . The adjusted HR for CRC-specific mortality was 0.61 (95 % CI, 0.31-1.19) but was not statistically significant (P trend=0.23), suggesting the alternative hypothesis that the improved outcome associated with higher concentrations of 25(OH)D could be explained by a beneficial effect of vitamin D on non-CRC-related conditions including cardiovascular disease and diabetes. However, most of the deaths in the analysis of overall mortality were caused by CRC, with only eight attributable to cardiovascular or cerebrovascular events. Moreover, a significant relationship between 25(OH)D and CRC survival was subsequently confirmed in another study of 1017 CRC patients in the NHS and HPFS, in which higher post-diagnosis vitamin D scores calculated from known clinical determinants of vitamin D status were found to be significantly associated with improved cancer-specific survival (adjusted HR 0.50; 95 % CI 0.26-0.95; P trend=0.02) and overall survival (HR 0.62; 95 % CI, 0.42-0.93; P trend=0.002) [47] . Studies performed on other cohorts have reproduced these findings, with HRs for overall and CRC-specific mortality very similar to those of the original reports [48, 49••, 50] . In sub-group analyses within the NHS and HPFS cohorts, the benefit of higher plasma 25(OH)D seemed greater for stage III and IV patients than stage I and II (adjusted HR 0.40 versus 0.90, respectively, comparing extreme quartiles) [46] . % of the study population had levels ≥33 ng mL −1 , the threshold believed to be required for a protective effect of vitamin D on CRC risk [36] . Possibly as a result of this skewed distribution of 25(OH)D, no significant association was detected between higher 25(OH)D levels and improved outcome in the NCCTG 9741 study. However, in a post-hoc exploratory subgroup analysis, patients who were randomized to receive FOLFOX chemotherapy and had 25(OH)D levels in the highest quartile had a multivariable HR of 0.64 (95 % CI, 0.45-0.90; P trend=0.003) for overall mortality compared with patients on FOLFOX with levels in the lowest quartile. Although the data above are intriguing and are generally consistent in suggesting a potential function for vitamin D in treating CRC, the possibility of reverse causation must be considered. A recent large meta-analysis of observational studies and randomized clinical trials of vitamin D status and multiple health outcomes, including cancer survival, was published in The Lancet Diabetes & Endocrinology [52] . The authors noted that, although prospective observational studies consistently revealed reductions in cardiovascular disease, serum markers of cardiovascular disease and inflammation, diabetes, infectious disease, and cancer incidence and mortality with higher concentrations of 25(OH)D, results of randomized intervention studies did not corroborate these findings. They hypothesized that low circulating 25(OH)D may therefore be a consequence of ill health, rather than the cause. Furthermore, systemic and local inflammation, which characterizes all the conditions listed above, may be the mechanism by which disease leads to low vitamin D concentrations. Although this is certainly plausible, results from the analysis of plasma 25(OH)D levels and CRC survival nested within the NHS and HPFS, discussed above, provide evidence against this hypothesis, because attempts were made to control for reverse causation [46] . In that paper, CRC patients who received their cancer diagnosis within two years of 25(OH)D measurement were excluded from the analysis, in case the presence of occult illness and cancer resulted in lower 25(OH)D values. Indeed, the significant relationship between 25(OH)D levels and survival was even preserved in sensitivity analyses that excluded patients who were diagnosed within five years of 25(OH)D assessment. However, further investigation of the relationship between vitamin D, inflammation, and CRC is clearly warranted.
As with chemoprevention, definitive evidence of the efficacy of vitamin D for treating CRC can only be obtained from rigorously-designed, randomized clinical trials. Given the prevalence of vitamin D deficiency and insufficiency among metastatic CRC patients, the hypothesis-generating finding of a greater benefit of vitamin D for advanced-stage patients, and the preclinical studies revealing potential synergy between vitamin D and cytotoxic drugs including platinums [53] [54] [55] [56] and 5-FU [57] , a randomized, double-blind phase II trial of ) vitamin D3 for previously untreated stage IV CRC patients has been designed, and is currently enrolling patients at multiple centers across the U.S. (ClinicalTrials.gov identifier NCT01516216). The primary endpoint is progression-free survival, and accrual of approximately 120 patients is planned. Serial plasma and DNA samples and archival tumor tissue will be collected from all patients and banked for future correlative studies to further investigate underlying molecular and genetic mechanisms within the context of a human intervention study.
Conclusion
The potential to modulate the development and progression of CRC by use of nutritional and lifestyle factors including vitamin D is very real, but insufficiently studied; a clinical and translational approach that goes beyond purely observational studies is required to establish causality. In addition, elucidation of a biological mechanism underlying these clinical findings would increase the acceptance of vitamin D as critical for cancer prevention and treatment. In this era of expensive and often toxic anti-neoplastic drugs, vitamin D is an attractive treatment option for patients and oncologists with respect to both safety and cost, and improved understanding of vitamin D in CRC could potentially greatly change the management of this disease.
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